Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Are there any restrictions on the tigecycline injection patent extension?

See the DrugPatentWatch profile for tigecycline

The antibiotic tigecycline, marketed under the brand name Tygacil, is used to treat various infections. According to DrugPatentWatch.com [1], the tigecycline injection patent was initially assigned to Wyeth (now part of Pfizer) in 2005.

However, with the Biologics Price Competition and Innovation Act of 2009 (BPCIA), the United States Patent and Trademark Office (USPTO) was directed to implement a patent term extension (PTE) for certain pharmaceutical and biotechnology products [2]. The PTE aims to extend the lifetime of patents covering pharmaceutical products by up to 5 years.

In the case of the tigecycline injection, the patent extension was granted in 2013 by the USPTO [3]. However, it's essential to note that the PTE doesn't guarantee the extension of the patent's expiration date, but rather allows the patent holder to delay its expiration by a specified period.

The exact expiration date of the tigecycline injection patent may vary depending on when it was originally filed and granted. To determine the most current information on the patent's status, it's best to refer to the US Patent and Trademark Office (USPTO) database or reputable patent tracking services.

To view the patent's assignment and expiration dates, you can visit DrugPatentWatch.com [1], a reliable source for tracking pharmaceutical patents, or consult the official USPTO database.

References:

[1] DrugPatentWatch.com. (n.d.). Tigecycline Patents. Retrieved from https://www.drugpatentwatch.com/brand/tigecycline

[2] U.S. Patent and Trademark Office (USPTO). (n.d.). Patent Term Extension. Retrieved from https://www.uspto.gov/patents-law-resources/patent-term-extension

[3] U.S. Patent and Trademark Office (USPTO). (2013). Patent No. US 7,956,292 B2. US Patent Office.

Sources:

1. https://www.drugpatentwatch.com/brand/tigecycline
2. https://www.uspto.gov/patents-law-resources/patent-term-extension
3. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,956,292.PN.&OS=PN/7,956,292&RS=PN/7,956,292



Other Questions About Tigecycline :

the impact of efflux pumps on the tigecycline-induced resistance How does tigecycline's effectiveness against b fragilis resistance compare to metronidazole s? Does prolonged tigecycline use impact therapy success? What bacteria may resist tigecycline with overuse? Are specific groups more susceptible to tigecycline related hepatic issues? Does tigecycline's effect on liver differ in elderly? How do tigecycline guidelines affect treatment outcomes?